Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study to examine if new eczema drug may prevent future development of asthma

19.11.2003


Children’s Memorial Hospital is the only Chicago site for a study to determine whether early treatment of eczema using one of a new class of anti-inflammatory drugs will prevent subsequent development of asthma and other allergic diseases. Prevalence of eczema, or atopic dermatitis, has tripled in the last few decades, in parallel with asthma. Investigators at Children’s Memorial are part of a national clinical trial involving 1,100 children, from 3 to 18 months old, to test pimecrolimus (Elidel), one of a new class of drugs called calcineurin inhibitors. Used in a cream form, pimecrolimus prevents the production of chemicals in the immune system that cause eczema symptoms, including redness, itching, cracking and bleeding.



The six-year prospective study, funded by Novartis, will be conducted in two stages. During the first three years a double blind study will compare the safety and effectiveness of pimecrolimus in conjunction with corticosteroid therapy for flare-ups, vs. corticosteroid therapy alone. Investigators hope that early treatment with pimecrolimus will reduce or prevent the need for corticosteroids. In the second three years, patients will be followed to see if they develop other allergic diseases, such as asthma, allergic rhinitis (hay fever), or allergic conjunctivitis (eye redness).

"The hope is that early and effective topical treatment of eczema in its early stages may help to prevent the later development of asthma, allergic rhinitis or allergic conjunctivitis," says Amy Paller, MD, lead site investigator and researcher at Children’s Memorial Institute for Education and Research. Paller, head of dermatology at Children’s Memorial, is professor of pediatrics and dermatology at Northwestern University’s Feinberg School of Medicine.


"While eczema develops from birth to about three years of age in most affected children, other allergies such as asthma, begin in early childhood, and hay fever begins even later," she says. "We know that 50 to 80 percent of children who have eczema in infancy or childhood go on to develop asthma or other allergic diseases later on, especially if others in their immediate family have allergic disease. But we don’t now why."

According to Paller, recent studies in mice have shown that when an allergenic substance, egg protein, was applied onto broken skin, the animals subsequently showed an allergic, asthma-like response in the lungs when exposed to the egg protein through lung inhalation. The lungs of mice whose skin had been exposed to salt water did not show an allergic response to the egg protein. This may indicate that allergenic substances that enter the bloodstream through untreated or poorly managed eczema can trigger later allergic responses, including asthma, hay fever and other conditions.

To be considered for the study, babies must have been diagnosed with eczema within the past three months, and have a parent or sibling with eczema, asthma, allergic rhinitis or allergic conjunctivitis.

Pimecrolimus has been tested for safety and effectiveness in hundreds of babies, and it is currently approved for use in eczema by the U.S. Food and Drug Administration for children as young as 2 years of age.

Children’s Memorial Institute for Education and Research is the research arm of Children’s Memorial Hospital and the center for pediatric research at Northwestern University. Children’s Memorial Hospital is the pediatric teaching hospital for Northwestern University’s Feinberg School of Medicine.

Ellen M. Hunt | EurekAlert!
Further information:
http://www.childrensmemorial.org/

More articles from Health and Medicine:

nachricht Correct antibiotic dosing could preserve lung microbial diversity in cystic fibrosis
22.02.2019 | Children's National Health System

nachricht Researchers find trigger that turns strep infections into flesh-eating disease
19.02.2019 | Houston Methodist

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: (Re)solving the jet/cocoon riddle of a gravitational wave event

An international research team including astronomers from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has combined radio telescopes from five continents to prove the existence of a narrow stream of material, a so-called jet, emerging from the only gravitational wave event involving two neutron stars observed so far. With its high sensitivity and excellent performance, the 100-m radio telescope in Effelsberg played an important role in the observations.

In August 2017, two neutron stars were observed colliding, producing gravitational waves that were detected by the American LIGO and European Virgo detectors....

Im Focus: Light from a roll – hybrid OLED creates innovative and functional luminous surfaces

Up to now, OLEDs have been used exclusively as a novel lighting technology for use in luminaires and lamps. However, flexible organic technology can offer much more: as an active lighting surface, it can be combined with a wide variety of materials, not just to modify but to revolutionize the functionality and design of countless existing products. To exemplify this, the Fraunhofer FEP together with the company EMDE development of light GmbH will be presenting hybrid flexible OLEDs integrated into textile designs within the EU-funded project PI-SCALE for the first time at LOPEC (March 19-21, 2019 in Munich, Germany) as examples of some of the many possible applications.

The Fraunhofer FEP, a provider of research and development services in the field of organic electronics, has long been involved in the development of...

Im Focus: Regensburg physicists watch electron transfer in a single molecule

For the first time, an international team of scientists based in Regensburg, Germany, has recorded the orbitals of single molecules in different charge states in a novel type of microscopy. The research findings are published under the title “Mapping orbital changes upon electron transfer with tunneling microscopy on insulators” in the prestigious journal “Nature”.

The building blocks of matter surrounding us are atoms and molecules. The properties of that matter, however, are often not set by these building blocks...

Im Focus: University of Konstanz gains new insights into the recent development of the human immune system

Scientists at the University of Konstanz identify fierce competition between the human immune system and bacterial pathogens

Cell biologists from the University of Konstanz shed light on a recent evolutionary process in the human immune system and publish their findings in the...

Im Focus: Transformation through Light

Laser physicists have taken snapshots of carbon molecules C₆₀ showing how they transform in intense infrared light

When carbon molecules C₆₀ are exposed to an intense infrared light, they change their ball-like structure to a more elongated version. This has now been...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Global Legal Hackathon at HAW Hamburg

11.02.2019 | Event News

The world of quantum chemistry meets in Heidelberg

30.01.2019 | Event News

Our digital society in 2040

16.01.2019 | Event News

 
Latest News

JILA researchers make coldest quantum gas of molecules

22.02.2019 | Physics and Astronomy

Understanding high efficiency of deep ultraviolet LEDs

22.02.2019 | Materials Sciences

Russian scientists show changes in the erythrocyte nanostructure under stress

22.02.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>